336 related articles for article (PubMed ID: 29432383)
1. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Some AM; Buabeng P; Vekemans J; Kotey A; Vandoolaeghe P; Cullinane M; Traskine M; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2020 Jun; 16(6):1464-1470. PubMed ID: 31951771
[TBL] [Abstract][Full Text] [Related]
4. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
[TBL] [Abstract][Full Text] [Related]
6. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults.
Moon JE; Ockenhouse C; Regules JA; Vekemans J; Lee C; Chuang I; Traskine M; Jongert E; Ivinson K; Morelle D; Komisar JL; Lievens M; Sedegah M; Garver LS; Sikaffy AK; Waters NC; Ballou WR; Ofori-Anyinam O;
J Infect Dis; 2020 Oct; 222(10):1681-1691. PubMed ID: 32687161
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
Abdulla S; Salim N; Machera F; Kamata R; Juma O; Shomari M; Kubhoja S; Mohammed A; Mwangoka G; Aebi T; Mshinda H; Schellenberg D; Carter T; Villafana T; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
Malar J; 2013 Jan; 12():11. PubMed ID: 23297680
[TBL] [Abstract][Full Text] [Related]
9. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.
von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S
Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084
[No Abstract] [Full Text] [Related]
10. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
[TBL] [Abstract][Full Text] [Related]
13. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
14. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
16. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
17. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01
Moon JE; Greenleaf ME; Regules JA; Debois M; Duncan EH; Sedegah M; Chuang I; Lee CK; Sikaffy AK; Garver LS; Ivinson K; Angov E; Morelle D; Lievens M; Ockenhouse CF; Ngauy V; Ofori-Anyinam O;
Vaccine; 2021 Oct; 39(43):6398-6406. PubMed ID: 34593270
[TBL] [Abstract][Full Text] [Related]
18. RTS,S/AS01
Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
Bejon P; Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Mshamu S; Lang T; Gould J; Dubois MC; Demoitié MA; Stallaert JF; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; von Seidlein L
N Engl J Med; 2008 Dec; 359(24):2521-32. PubMed ID: 19064627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
